Showing results (471-480 of 744) with videos related to

Sort By:
Pageof 75
BJU International|August 30, 2014
Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancerChristopher M Booth, D Robert Siemens, Xuejiao Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance programAshley E Ross, Stacy Loeb, Patricia Landis, et al.
European Urology|November 24, 2016
New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate CancerWon Sik Ham, Heather J Chalfin, Zhaoyong Feng, et al.
The Prostate|May 16, 2018
ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63Alba Torres, Mohammed Alshalalfa, Elai Davicioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarrayMartin J Romeo, John Wunderlich, Lien Ngo, et al.
The Journal of Urology|November 17, 2016
The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific MortalityWon Sik Ham, Heather J Chalfin, Zhaoyong Feng, et al.
Human Pathology|October 23, 2012
Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladderNilda D Gonzalez-Roibon, Alcides Chaux, Turki Al-Hussain, et al.
Pathology|July 8, 2008
The Symphony protocol for H&E staining of prostatic adenocarcinoma on needle biopsy: a multicentre analysis of 120 casesAdeboye O Osunkoya, Donna E Hansel, Anil V Parwani, et al.
Pageof 75